



CoaguChek® INRange *at work...*

*Help your patients on
vitamin K antagonist (VKA)
therapy spend less time waiting
and more time INRange.*





CoaguChek INRange is your new standard in VKA monitoring

Proven, dependable CoaguChek® technology delivers consistently accurate PT/INR values to your hands.

- Make immediate treatment decisions with results transmitted by your patient directly to you using Bluetooth technology and the INRange app—**the first of its kind**
- Get reliable results by using the same brand of meter—**every time**
- Minimal training is required, so you can be confident your patients are ready and able to self-test—**safely**
- Patients can test on their prescribed schedule from wherever they happen to be—**more frequently**





More control. More engaged patients. More time in range.

- **More frequent testing can give you and your patients greater control over their INR stability¹**
 - It has been demonstrated that 50–60% of patients can be expected to remain in their target range if monitoring of INR occurs monthly, 77–85% if monitored weekly, and up to 92% if monitored every 3 days²
- **Frequent testing is more feasible for self-testers¹**
 - For most patients, traveling to a lab, clinic, or physician's office to test two or four times per month is inconvenient
- **Because results are immediate, patient self-testing can reduce anxiety and provide a sense of control**
 - Engaging patients in their own therapy can empower them to modify their lifestyles¹


Patients who self-test are more engaged in their own care, test more often, and spend more time in range.³




When you're connected, they're on track

You'll be *truly* connected to your patients, so you can confidently optimize their therapy.

- Evidence suggests that patients who have **a good connection with their healthcare professionals** adhere better to their therapy²
- It has been proven that patients who adhere to their prescribed testing schedule spend **more time in range**, which results in a lower incidence of stroke or bleeding³
- **Trend Report** tracks results to help you identify patterns so you can detect any drift in INR to provide more stable anticoagulation control¹



On meter




Online



CoaguChek INRange keeps you and your VKA patients connected

- **Bluetooth technology** keeps you connected by enabling patients to transmit their results from their meter directly to you so you can keep patients on track and in range—anytime, anywhere
- **Built-in reminders** for testing, medication, and appointments help keep patients compliant



Studies have indicated an improvement in some quality-of-life measures and patient satisfaction as a result of self-monitoring of anticoagulation^{2,4}

Enable your patients to self-test their PT/INR whenever, wherever—for confident control of their VKA therapy.



Now, there's one more reason your patients on VKA therapy should self test

Patient self-testing is safe, accurate and reliable, thanks to CoaguChek technology and quality.

- Patients with long-term indications for warfarin therapy and a target INR should be considered for self-monitoring⁵
- Patients receiving long-term warfarin therapy be given devices to self-monitor their coagulation status⁶
 - In a meta-analysis of 26 randomized controlled trials (published in 45 papers) with a total of 8,763 participants, CoaguChek was used in 85% of the trials
 - Self-monitoring patients spent a significantly higher percentage of time in therapeutic range



Liberate your VKA patients from the lab and discover the new standard in patient self-testing

- You can be confident in patient self-testing, knowing you are seeing and managing your patients' results as they are transmitted from their CoaguChek INRange meters
- Patient self-testing is safe, accurate and reliable, thanks to CoaguChek technology and quality
- Patient self-testing with CoaguChek INRange allows you to prescribe more frequent testing, while freeing patients from the lab, which can help them stay in range longer
- Studies have shown a lower incidence of stroke and a significant improvement in thromboembolic events in patient self-testers³

Now, with CoaguChek INRange, there is no need for frequent laboratory visits, which is one more reason to enable your VKA patients to test whenever, wherever.

References:

1. Ward A, Tompson A, Fitzmaurice D, Sutton S, Perera R, Heneghan C. Cohort study of Anticoagulation Self-Monitoring (CASM): a prospective study of its effectiveness in the community. *Br J Gen Pract.* 2015;65(636):e428-437.
2. Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. *Br J Haematol.* 2004;126(4):557-654.
3. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. *Lancet.* 2012;379:322-334.
4. Sharma P, Scotland G, Cruickshank M, et al. The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation. *Health Technol Assess.* 2015;19(48):1-172.
5. Jennings I, Kitchen D, Keeling D, et al. Patient self-testing and self-management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology. *Br J Haematol.* 2014;167(5):600-607.
6. National Institute for Health and Care Excellence. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor). <http://www.nice.org.uk/Guidance/DG14>. September 2014.

COAGUCHEK is a trademark of Roche.

© 2019 Roche.

www.coaguchek.com

For Health Care Professionals only
MC-HR-00288

CoaguChek[®]
